Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Revelation Biosciences Inc WT (REVBW)

Revelation Biosciences Inc WT (REVBW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering Globe Newswire - Fri Jul 29, 2022

SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering Globe Newswire - Tue Jul 26, 2022

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis Globe Newswire - Fri Jul 22, 2022

SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis Globe Newswire - Mon Jun 13, 2022

-Data anticipated in Q3 2022-...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress Globe Newswire - Mon May 16, 2022

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update Globe Newswire - Wed Apr 6, 2022

-CLEAR Study enrollment ongoing top-line data expected 2H 2022- -Diagnostic partnering discussions ongoing- SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE)...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection Globe Newswire - Wed Mar 30, 2022

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference Globe Newswire - Mon Feb 7, 2022

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
Revelation Biosciences Raises $7.76 Million in Equity Financing Globe Newswire - Mon Jan 24, 2022

SAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0143 (unch)
REVB : 2.37 (+0.85%)
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company Globe Newswire - Thu Jan 13, 2022

-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro...

REVB : 2.37 (+0.85%)
REVBW : 0.0143 (unch)

Barchart Exclusives

2 Small-Cap Stocks With 40% to 60% Upside Barchart - Sat May 4, 2:45PM CDT
Wall Street believes these two growth stocks will soar, driven by the demand for their products. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot